Seres therapeutics announces completion of patient enrollment for ser-155 phase 1b cohort 2 clinical trial in allogenic hsct

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled cohort 2 of its phase 1b trial of ser-155 in patients who received allogeneic hematopoietic stem cell transplantation (allo hsct). ser-155 is an orally administered, consortium of bacteria, cultivated from cell banks and designed to reduce the incidence and severity of enteric-derived infections and resulting.
MCRB Ratings Summary
MCRB Quant Ranking